Arcadia Biosciences

Americans get an average of one-fifth, or 400 calories, per day from wheat; according to the United Nations, bread wheat accounts for 20 percent of the human diet globally.

The company offers a portfolio of products.

Eric Rey, CEO of Arcadia Biosciences, talks about a proprietary technology called TILLING which helps to produce “tomatoes that can be plucked when they are ripe and stay fresh as they are transported to market.” Read the full article

UC Davis plant scientist Eduardo Blumwald is working to feed and fuel the world with new grants totaling $8.4 million from the U.S. Department of Energy, U.S. Agency for International Development and industry partners.

The company posts current job opportunities as they become available.

Kevin Comcowich chairs Arcadia’s board of directors and has served as a director since October 2016. He most recently served as chief executive officer and portfolio manager of HTX.

The company cultivates next-generation wellness products, drawing on its roots in agricultural innovation.

Arcadia Biosciences, 5956 Sherry Lane, Suite 2000 Dallas, TX 75225 Main: (530) 756-7077 Fax: (530) 756-7027 info@arcadiabio.com

Since 2002, the company has developed ingredients intended to meet consumer demand for healthier choices. It also cultivates wellness products, drawing on its roots in agricultural innovation.

Arcadia Biosciences reports minimal operating cash burn of **$319K** in Q2 2026, securing **$4 million** in a private placement to end the quarter with **$4.2 million** in cash. The company’s **Zola®** product achieves **$740K in monthly sales in July**, surpassing **$1 million** in the first week of August. These updates highlight operational efficiency and revenue growth in its core offerings.

Aug 2026Arcadia BiosciencesNews article

Arcadia Biosciences completes a $4 million private placement of 3.88 million shares (or pre-funded warrants) under Nasdaq’s at-the-market pricing rules. The company, listed on Nasdaq as RKDA, specializes in wellness products. The transaction follows a prior announcement of the offering.

Jun 2026Arcadia BiosciencesNews article

Arcadia Biosciences secures a $4 million private placement through Nasdaq’s at-the-market rules, selling 3.88 million shares of common stock or pre-funded warrants. The company, which develops wellness products, executes securities purchase agreements to facilitate the transaction. This follows Nasdaq’s framework for continuous share issuance without a fixed price.

Jun 2026Arcadia BiosciencesNews article

Arcadia Biosciences reports an 18% year-over-year increase in Zola® product volumes. The company achieves its lowest-ever SG&A expenses while maintaining growth in its wellness product line. Financial and operational highlights reflect strong performance in the first quarter of 2026.

May 2026Arcadia BiosciencesNews article